Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Tempus AI, Inc. is a technology-driven precision medicine company that applies artificial intelligence and advanced analytics to clinical and molecular data to support personalized healthcare. The company operates at the intersection of healthcare, biotechnology, and artificial intelligence, focusing primarily on oncology and, to a growing extent, neuropsychiatric and other complex diseases. Its core value proposition is the aggregation and analysis of large-scale, multimodal clinical and genomic datasets to inform diagnosis, treatment selection, and clinical research.
Tempus AI was founded in 2015 by Eric Lefkofsky with the objective of closing the gap between data generation and data utilization in medicine. The company has evolved from a genomics-focused diagnostics provider into an integrated data and analytics platform supporting physicians, researchers, and life sciences companies. Tempus AI became a publicly traded company in June 2024 following its initial public offering and is listed on the Nasdaq under the ticker symbol TEM.
Business Operations
Tempus AI generates revenue primarily through clinical testing, data licensing, and technology-enabled services for healthcare providers, pharmaceutical companies, and academic institutions. Its operations center on next-generation sequencing, molecular diagnostics, and AI-driven data analytics, delivered through its operating subsidiary Tempus Labs, Inc. The company supports oncologists and other clinicians by providing laboratory-developed tests, biomarker analysis, and decision-support tools integrated into clinical workflows.
In addition to clinical services, Tempus AI partners with biopharmaceutical companies to support drug discovery, biomarker development, and clinical trial optimization. These partnerships leverage Tempus’s proprietary datasets and machine learning models. The company also maintains capabilities in medical imaging and digital pathology following strategic acquisitions, expanding its multimodal data platform beyond genomics into radiology and phenotypic analysis.
Strategic Position & Investments
Tempus AI’s strategic direction emphasizes scaling its data platform, expanding disease coverage, and deepening relationships with life sciences companies. Growth initiatives include increasing test volumes, enhancing AI models with longitudinal real-world data, and embedding Tempus tools more deeply into provider and research ecosystems. The company positions itself as a data infrastructure layer for precision medicine, differentiating through the breadth, depth, and clinical annotation of its datasets.
Notable acquisitions include Ambry Genetics, which strengthened Tempus’s hereditary cancer and rare disease testing capabilities, and Arterys, which added FDA-cleared medical imaging AI technologies. These investments reflect Tempus AI’s focus on multimodal data integration and emerging applications of AI across diagnostics, imaging, and clinical research.
Geographic Footprint
Tempus AI is headquartered in Chicago, Illinois, with primary laboratory, engineering, and commercial operations in the United States. The company serves healthcare providers and research partners across major U.S. regions, with a particularly strong presence in large academic medical centers and oncology networks.
Internationally, Tempus AI’s footprint is more limited and primarily involves data partnerships, research collaborations, and life sciences customers outside the U.S. The company’s core clinical testing operations are U.S.-based, while its data and analytics offerings support multinational pharmaceutical clients with global development programs.
Leadership & Governance
Tempus AI is led by its founder, who has maintained a central role in defining the company’s long-term vision of data-driven healthcare transformation. The leadership team combines experience in technology, healthcare operations, and public company governance, reflecting the company’s dual identity as both a healthcare services provider and an AI platform company.
Key executives include:
- Eric Lefkofsky – Founder, Chairman, and Chief Executive Officer
- Ryan Fukushima – President and Chief Operating Officer
- Jim Rogers – Chief Financial Officer
The leadership philosophy emphasizes long-term investment in data assets, rigorous scientific validation, and the responsible application of artificial intelligence in clinical settings.